Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | GPR183 | P32249 | 3/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2486851 | 0.99 | ACHE (0.74) | ACHEMEN1KMT2AGPR183L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2486850 | 0.99 | ACHE (0.74) | ACHEMEN1KMT2AGPR183L3MBTL1 | |
| SCHEMBL2485396 | 0.88 | ACHE (0.61) | ACHEMEN1KMT2AGPR183 | |
| SCHEMBL5707169 | 0.86 | MEN1 (0.85) | ACHEMEN1KMT2AGPR183L3MBTL1 | |
| SCHEMBL3159223 | 0.86 | MEN1 (0.85) | ACHEMEN1KMT2AGPR183L3MBTL1 | |
| SCHEMBL2485549 | 0.82 | GPR183 (0.67) | MEN1KMT2AGPR183 | |
| SCHEMBL10971222 | 0.81 | ACHE (0.53) | ACHE | |
| Hydrochloric Acid SCHEMBL2487345 | 0.81 | TDP1 (0.66) | MEN1KMT2AGPR183 | |
| SCHEMBL2485319 | 0.81 | ACHE (0.74) | ACHE | |
| Hydrochloric Acid SCHEMBL2487347 | 0.81 | TDP1 (0.66) | MEN1KMT2AGPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061452-B1 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-10-26 | — | — | EP | claimed |
| US-20100010002-A1 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-01-14 | — | — | US | claimed |
| EP-2061452-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | Piramal Life Sciences Limited (IN) | 2009-05-27 | — | — | EP | claimed |
| WO-2008026125-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-06 | — | — | WO | claimed |
| EP-2061452-B1 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-10-26 | — | — | EP | disclosed |
| US-20100010002-A1 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-01-14 | — | — | US | disclosed |
| EP-2061452-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | Piramal Life Sciences Limited (IN) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008026125-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010002-A1 | ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES | ABL1, MCL1, SRC | ACHE 4675/4885MEN1 3219/4885KMT2A 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.